The active-manager buying cluster (Morgan Stanley, Nuveen, Citigroup, Russell) suggests conviction at current levels, but the mega-passive selling by Fidelity and T. Rowe Price creates a tug-of-war. Monitor for any catalyst (earnings, pipeline update) that could break the stalemate. The 45-day 13F reporting lag means these positions may already be adjusted — watch for insider buying as a confirming signal.
Executive Summary
Aktis Oncology (AKTS) saw a mixed institutional cluster in Q2 2026, with 6 buyers adding $3.9M in net new positions (led by Morgan Stanley and Nuveen) while 3 sellers reduced holdings by $2.4M (led by Fidelity trimming 100K+ shares). The buying was dominated by active asset managers doubling positions, while selling came from mega-passive funds trimming. This divergence suggests active managers see value at current levels, but passive rebalancing is reducing exposure. The stock has been volatile historically, with past reports showing poor T+20 performance, so the signal is moderate despite the active-manager conviction.
Key Financial Metrics
Institutional Positions
Net institutional flow: $1.5M
▲ Buyers (6)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | DOUBLED | +103.9% | $2.0M | $1.4M |
| Nuveen | DOUBLED | +103.6% | $1.6M | $1.2M |
| Deutsche Bank | ADD | +49.3% | $678.0K | $426.0K |
| Citigroup | DOUBLED | +1193.1% | $425.0K | $407.0K |
| Russell Investments Group | DOUBLED | +399.9% | $250.0K | $222.0K |
| New York State Common Retirement Fund | DOUBLED | +134.4% | $242.0K | $185.0K |
▼ Sellers (3)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Fidelity | TRIM | -26.1% | $6.9M | $2.3M |
| Goldman Sachs | TRIM | -29.5% | $540.0K | $146.0K |
| T. Rowe Price | TRIM | -51.2% | $28.0K | -$3.4K |
Key Facts
- 6 institutional buyers added $3.9M in net new positions in Q2 2026
- 3 institutional sellers reduced holdings by $2.4M, led by Fidelity trimming 100,748 shares
- Morgan Stanley doubled its position to 62.6K shares worth $2.0M
- Nuveen doubled to 49.8K shares worth $1.6M
- Fidelity remains the largest holder at 285.6K shares worth $9.2M despite trimming
- T. Rowe Price cut its position by 51.2% to 763.5K shares
- Active asset managers (Citigroup, Russell, Deutsche Bank) all added significantly
- No insider open-market buying was detected in the same period
Financial Impact
Net institutional buying of $3.9M by 6 buyers vs $2.4M in selling by 3 sellers, for a net inflow of approximately $1.5M
Risk Factors
- 45-day 13F reporting lag means positions may have already been unwound
- Historical T+20 performance on AKTS reports has been poor (avg -2.53%)
- Passive fund selling could continue to pressure the stock
- No insider buying to confirm institutional conviction
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-AKTS-2026-Q2 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 15, 2026 6w ago | Institutional Cluster | $24.72 $22.41 | ▼ −9.34% | ▼ −7.37% | — |
Jul 10, 2026 12w ago | Insider Cluster | $27.88 $24.13 | ▼ −13.45% | ▼ −15.88% | — |
May 21, 2026 19w ago | Press Release | $20.34 $24.48 | ▲ +20.35% | ▲ +21.77% | — |
May 11, 2026 20w ago | 8-K | $19.73 $18.58 | ▼ −5.83% | ▼ −4.10% | — |
Apr 21, 2026 23w ago | Press Release | $22.00 $18.50 | ▼ −15.91% | ▼ −19.07% | — |
Mar 30, 2026 26w ago | Press Release | $17.89 $18.87 | ▲ +5.48% | ▼ −3.94% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access